New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
16:08 EDTPDIIPDI, Inc. subsidiary acquires miRInform test assets from Asuragen
PDI, Inc. announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRInform Thyroid and Pancreas cancer test assets from privately held Asuragen. This acquisition marks the execution of PDI's strategy to create a commercially driven molecular diagnostics business and a commitment to developing new solutions for the thyroid and pancreatic cancer testing markets. This transaction includes the miRInform Thyroid and Pancreas tests, intellectual property related to these and other tests in development for thyroid cancer, and an extensive 5,000 plus tissue sample biobank to support life cycle management efforts. Terms of the transaction include $8M in upfront cash, future commercial milestone-based payments and royalties.
News For PDII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 16, 2015
06:33 EDTPDIIPDI, Inc. announces continued Medicare coverage for PancraGEN
PDI, Inc. subsidiary, Interpace Diagnostics, announced that Novitas Solutions, the Medicare Administrative Contractor, or MAC, for Interpace Diagnostics, has updated its Local Coverage Determination, or LCD, for PancraGEN. The PancraGEN test utilizes the PathFinderTG platform. The original coverage issued on November 5, 2010 provided "Coverage with Appropriateness Development," which required the company to routinely present updated data to further validate the test's effectiveness. The new policy no longer includes this condition for coverage and is effective December 31 and ensures continued coverage of PancraGEN for Medicare eligible patients. This updated coverage was achieved due to the increasing body of evidence including the publication of the results of the pivotal PancraGEN 492 patient multicenter National Pancreatic Cyst registry clinical validation study in the February 2015 issue of Endoscopy.i The study concluded that PancraGEN is 90% accurate at predicting benign and malignant disease in patients with pancreatic cysts, providing important insights into patients' likelihood of developing pancreatic cancer.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use